Dualitas Therapeutics

🗓 Founded 2023👥 15 employees💰 Last funded Dec 2022
Biotechnology Research🌐 dualitastx.com
Website LinkedIn
Dualitas Therapeutics is a biotechnology company pioneering the future of bispecific antibody therapies for immune and inflammatory (I&I) diseases and beyond. Powered by our proprietary DualScreen™ discovery engine and a growing library of novel cell surface proximity engagers, our pipeline—including lead programs DTX-103 and DTX-102—has demonstrated compelling preclinical evidence supporting its potential to address important unmet patient needs. We offer partnering opportunities on the next generation of bispecific therapies in I&I diseases – and beyond.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2023
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Dualitas Therapeutics?
Dualitas Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Dualitas Therapeutics last raise funding?
The most recent investment in Dualitas Therapeutics recorded on gritt.io was in December 2022.
When was Dualitas Therapeutics founded?
Dualitas Therapeutics was founded in 2023.
What industry is Dualitas Therapeutics in?
Dualitas Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.